Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A
Sapreme presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society.
Sapreme Appoints Henrik Luessen as Chief Business Officer
Sapreme Appoints Miriam Bujny as Chief Development Officer
Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors